Global private equity and venture capital news and research

3i completes $700m sale of Xellia Pharmaceuticals to Novo Group

21 May 2013

UK private equity firm 3i has completed its previously announced exit for Denmark's Xellia Pharmaceuticals with its sale to Novo Group for $700m, returning 2.3 times the money.

Sorry, to get access to this you need to subscribe for free.

In order to view more content, sign-up to our free daily newsletter.

If you would like to read the premium stories, have complete access to our breaking news and Limited Partner magazine you need to become a Premium Subscriber.

Subscribe to AltAssets today

Login to AltAssets

Legals & Terms of UsePrivacy Policy

AltAssets is registered as a trademark of Investor Networks Limited (06695690).
Registered Office: WeWork 4001, 1 Fore Street, London, EC2Y 5EJ
Content is © AltAssets 2000-2016